Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 11/20 | 0.34 |
| ▸ | PTAFR | P25105 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 3/20 | 0.33 |
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22280910 | 0.96 | KDM4E (0.34) | TNK2PTAFRBTKDRD1TACR1 | |
| SCHEMBL22281107 | 0.95 | DRD1 (0.33) | TNK2PTAFRBTKDRD1KDM4E | |
| SCHEMBL22280691 | 0.93 | TNK2 (0.31) | TNK2PTAFRBTKDRD1KDM4E | |
| SCHEMBL22281206 | 0.90 | DRD1 (0.33) | TNK2PTAFRBTKDRD1KDM4E | |
| SCHEMBL22281108 | 0.90 | PDE4A (0.32) | TNK2DRD1MEN1ALDH1A1KMT2A | |
| SCHEMBL22280697 | 0.89 | ALDH1A1 (0.33) | DRD1ALDH1A1 | |
| SCHEMBL22280913 | 0.89 | PTAFR (0.31) | TNK2PTAFRBTKDRD1KDM4E | |
| SCHEMBL22280688 | 0.87 | ALDH1A1 (0.39) | TNK2PTAFRKDM4EMEN1ALDH1A1 | |
| SCHEMBL22280917 | 0.86 | PDE4A (0.32) | DRD1MEN1ALDH1A1KMT2A | |
| SCHEMBL22280933 | 0.85 | TNK2 (0.40) | TNK2BTKTACR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239505-A1 | BLUE PHOSPHORESCENT EMITTERS EMPLOYING FUNCTIONALIZED IMIDAZOPHENTHRIDINE AND ANALOGUES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239505-A1 | BLUE PHOSPHORESCENT EMITTERS EMPLOYING FUNCTIONALIZED IMIDAZOPHENTHRIDINE AND ANALOGUES | EML4, TYR, TYMP | TNK2 1916/4885PTAFR 3073/4885BTK 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.